

AD _____

Award Number: W81XWH-10-1-0052

TITLE: Deineating the effect of anti-Fas on the Fas-mediated stem cell differentiation.

PRINCIPAL INVESTIGATOR: Michael Dellinger

CONTRACTING ORGANIZATION:

UT Southwestern Medical Center
Dallas, TX 75390

REPORT DATE: February 2013

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE 02-08-2013		2. REPORT TYPE Annual Summary		3. DATES COVERED 15January2010-14January2013	
4. TITLE AND SUBTITLE Delineating the Effect a Novel Anti-VEGF-A Therapy Has on the Lymphatic System of Immunocompetent Tumor-Bearing Mice.				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-10-1-0052	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Michael Dellinger E-Mail: michael.dellinger@utsouthwestern.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) UT Southwestern Medical Center Dallas, TX 75390				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Despite intense research efforts, cancer remains the second leading cause of death in the United States. Mortality is seldom caused by primary tumors, but rather by the effect of metastases on distant organs. The lymphatic system serves as a common route of metastasis for many cancers of epithelial origin. There is growing evidence that lymphangiogenesis, the sprouting of new lymphatics from pre-existing lymphatics, facilitates the dissemination of cancer. Interestingly, vascular endothelial growth factor receptor-2 (VEGFR2) signaling has been shown to stimulate lymphangiogenesis in adult mice. However, the role VEGFR2 serves in the development of the lymphatic system has not been defined. Here we use the <i>Cre-lox</i> system to show that the proper development of the lymphatic vasculature requires VEGFR2 expression by lymphatic endothelium. This newly identified function of VEGFR2 further defines the molecular pathways controlling the development of the lymphatic vasculature and sheds light on how therapeutic agents targeting VEGFR2 can inhibit tumor lymphangiogenesis.					
15. SUBJECT TERMS VEGF-A, VEGFR2, lymphangiogenesis, tumor lymphangiogenesis					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	17	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	6
Reportable Outcomes.....	7
Conclusion.....	7
References.....	8
Appendices.....	9

INTRODUCTION:

Despite intense research efforts, cancer remains the second leading cause of death in the United States. Mortality is seldom caused by primary tumors, but rather by the effect of metastases on distant organs. The lymphatic system serves as a common route of metastasis for many cancers of epithelial origin. There is growing evidence that lymphangiogenesis, the sprouting of new lymphatics from pre-existing lymphatics, facilitates the dissemination of cancer. Interestingly, the growth factor VEGF-A stimulates lymphangiogenesis; however, the underlying mechanisms have not been fully defined. To achieve a better understanding of VEGF-A's function in biology, our lab helped develop a novel anti-VEGF-A antibody (r84) that specifically blocks mouse and human VEGF-A activation of VEGFR2, but not VEGFR1. During the course of this fellowship I have used r84 to delineate the cellular and molecular mechanisms underlying VEGF-A-induced lymphangiogenesis and to characterize the effect of anti-VEGF-A therapy on the lymphogenous spread of breast cancer (Dellinger and Brekken, 2011). Additionally, I have used the *Cre-Lox* system to conditionally inactivate VEGFR2 in lymphatic endothelial cells to identify the direct role VEGFR2 serves in promoting lymphangiogenesis.

BODY:

Conditional inactivation of Vegfr2 in lymphatic endothelium causes lymphatic hypoplasia

Lyve-1^{Cre} mice were recently developed to conditionally delete *floxed* (flanking *loxP*) DNA sequences in LECs [1]. However, the removal of *floxed* DNA sequences in collecting lymphatic vessels and valves was not previously analyzed. To further characterize the pattern of *Cre*-mediated recombination in *Lyve-1^{Cre}* mice, we crossed this strain with the *mT/mG* reporter strain. In *mT/mG* mice, *Cre* recombinase induces the excision of a membrane-targeted tdTomato (*mT*) cassette and expression of a membrane-targeted GFP cassette (*mG*) [2]. Ear skin whole-mounts from *Lyve-1^{wt/Cre};mT/mG* mice displayed strong GFP expression in macrophages as well as lymphatic capillaries and collecting lymphatic vessels and valves (Figure 1A,B). This result indicates that the *Lyve-1^{Cre}* mouse can be used to effectively excise *floxed* sequences in LECs located in the different branches of the lymphatic tree.

To investigate the function of *Vegfr2* in the development of the lymphatic system, *Lyve-1^{Cre}* mice were bred with *Vegfr2* *floxed* mice (*Vegfr2^{fllox}*). Immunofluorescence staining of ear skin from adult mice revealed that all *Lyve-1*-positive dermal lymphatic vessels lacked *Vegfr2* in *Lyve-1^{wt/Cre};Vegfr2^{fllox/fllox}* mice (Figure 1C-H). *Vegfr2* expression by dermal blood vessels was unaffected in *Lyve-1^{wt/Cre};Vegfr2^{fllox/fllox}* mice (Figure 1C-H). Whole-mount immunofluorescence staining of ear skin for *Lyve-1* showed a highly branched network of lymphatic capillaries in *Vegfr2^{fllox/fllox}* mice (Figure 2A). Conversely, *Lyve-1^{wt/Cre};Vegfr2^{fllox/fllox}* mice exhibited a hypoplastic network of lymphatic capillaries (Figure 2B). Quantitative analysis showed that there were significantly fewer lymphatic branch points in the ear skin of *Lyve-1^{wt/Cre};Vegfr2^{fllox/fllox}* mice (6.042 ± 0.198 , $n = 6$) than *Vegfr2^{fllox/fllox}* mice (11.29 ± 0.940 , $n = 6$) (Figure 2C). However, lymphatic vessel diameter was not slightly different between *Lyve-1^{wt/Cre};Vegfr2^{fllox/fllox}* mice ($52.65 \mu\text{m} \pm 1.303$, $n = 6$) and *Vegfr2^{fllox/fllox}* mice ($49.05 \mu\text{m} \pm 1.675$, $n = 6$) (Figure 2D).

Vegfr2 is not required for the maturation of collecting lymphatic vessels

Lymphatic capillaries and collecting lymphatic vessels are differentially covered by SMCs. *Lyve-1*-positive lymphatic capillaries are free of SMCs whereas *Lyve-1*-down-regulated

collecting vessels are covered by SMCs. Interestingly, defects in the patterning of the lymphatic vasculature have been associated with the mislocalization of SMCs on Lyve-1-positive lymphatic vessels [3-5]. To determine whether the hypoplastic lymphatic network in *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* mice was covered by SMCs, we stained ear skin from adult mice for Lyve-1 and smooth muscle actin (SMA). This revealed that the Lyve-1-positive lymphatic networks in *Vegfr2^{flox/flox}* and *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* mice were not surrounded by SMCs (Figure 3A,B; n = 3 for each genotype). However, SMCs were properly associated with Lyve-1-down-regulated vessels in both strains of mice (data not shown).

Next we evaluated whether *Vegfr2* is required for formation of lymphatic valves. Whole-mount immunofluorescence staining of adult ear skin for Lyve-1 and CD31 showed that Lyve-1-positive CD31-positive initial lymphatic vessels transitioned into Lyve-1-negative CD31-positive collecting lymphatic vessels in *Vegfr2^{flox/flox}* and *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* mice. Importantly, CD31-positive collecting lymphatic vessels in *Vegfr2^{flox/flox}* and *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* mice possessed normal appearing lymphatic valves consisting of a bulbous region containing intraluminal leaflets (Figure 3C,D; n = 4 for each genotype). The CD31 staining also revealed that the patterning of the blood vasculature was normal in *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* mice (Figure 3E,F; n = 4 for each genotype).

Lymphatic function is normal in mice lacking Vegfr2 in lymphatic endothelium

The dramatic reduction in lymphatic vessel density led us to assess lymphatic function in *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* mice. Evans blue dye (EBD) was injected into the hind paws of *Vegfr2^{flox/flox}* and *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* mice and was rapidly transported to the popliteal and iliac lymph nodes in both strains of mice (Figure 4; n = 6 of each genotype). EBD dye did not reflux into the mesenteric lymph nodes of *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* mice, indicating that lymphatic valves functioned properly in these mice. Additionally, *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* mice did not exhibit lymphedema, chylous ascites or chylothorax.

Lyve-1^{wt/Cre};Vegfr2^{flox/flox} embryos display reduced viability and blood vessel defects

While expanding our mouse colony we found that the viability of *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* mice was dramatically reduced. Only 12.8% of the expected frequency of *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* mice were present at weaning (Table 1 and Figure 5A). Therefore we performed a time course experiment to determine when *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* mice begin to die. We found that *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* embryos were present at their expected frequencies at E12.5 and E14.5, but were only found at 40.6% and 34.5% of their expected frequencies at E16.5 and E18.5, respectively (Table 1 and Figure 5A). To determine whether impaired development of the lymphatic system was responsible for the lethal phenotype of *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* mice, we evaluated whether the jugular lymph sacs had formed properly in these embryos. This analysis was performed because mice that fail to form jugular lymph sacs develop severe edema and die during embryogenesis [6, 7]. At E14.5, the jugular lymph sacs were present and of normal size in *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* embryos (Figure 5B,C). At E16.5, the density of podoplanin positive dermal lymphatic vessels was not significantly different between *Vegfr2^{flox/flox}* (2.81 ± 0.157 ; n = 6) and *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* embryos (2.79 ± 0.513 ; n = 6; Figure 5D-F). Importantly, immunofluorescence staining of E14.5 and E16.5 embryos revealed that a majority of the LECs in *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* embryos did not express *Vegfr2* (Data not shown). Furthermore, none of the mutant embryos exhibited edema at any of the time points analyzed (Figure 5G-I). Therefore, lymphatic defects do not appear to be responsible for the demise of *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* embryos.

We next turned our attention to other tissues that express Lyve-1 to identify changes that could be responsible for the lethal phenotype of *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* embryos. Lyve-1 has recently been reported to be expressed by BECs in the yolk sac and liver [8]. Indeed, crosses with *mT/mG* reporter mice demonstrated that *Lyve-1^{wt/Cre}* mice display *Cre* recombinase activity in BECs in these tissues (data not shown). To determine whether the vasculature was altered in these tissues, we performed immunohistochemistry with markers of BECs. Whole-mount immunofluorescence staining for CD31 revealed that there was a 61.3% decrease in the number of branch points in yolk sacs isolated from E12.5 *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* embryos (41.06 ± 3.662 , $n = 4$) compared to *Vegfr2^{flox/flox}* embryos (106.3 ± 3.157 , $n = 3$) (Figure 6A-C). Additionally, immunohistochemistry of E14.5 livers for endomucin showed that there were significantly fewer blood vessels in *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* embryos (27.00 ± 4.263 , $n = 4$) than *Vegfr2^{flox/flox}* embryos (45.88 ± 2.850 , $n = 4$) (Figure 6D-F).

Vegfr2 is not expressed by macrophages and inactivation of Vegfr2 in the myeloid lineage does not affect lymphatic development

Crosses with *mT/mG* reporter mice revealed that *Lyve-1^{Cre}* mice exhibit *Cre* recombinase activity in macrophages as well as lymphatic vessels (Figure 1A,B). Therefore, several experiments were performed to rule out the possibility that the lymphatic phenotype of *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* mice was due to the inactivation of *Vegfr2* in macrophages. First, we explored the expression of *Vegfr2* by macrophages. Whole-mount immunofluorescence staining showed that *Vegfr2* was not expressed by macrophages in the ear skin of *Vegfr2^{wt/GFP}* mice (Figure 7). Next, the *LysM^{Cre}* strain was used to conditionally delete target sequences in the myeloid lineage. *LysM^{Cre}* mice were bred with *mT/mG* reporter mice to characterize the expression pattern of *Cre* recombinase and to trace the fate of cells of the myeloid lineage. All *LysM^{wt/Cre};mT/mG* mice displayed strong GFP expression by macrophages in the ear skin (Figure 8). GFP did not co-localize with *Vegfr3* in the ear skin of *LysM^{wt/Cre};mT/mG* mice (Figure 8; $n = 5$ mice). This finding indicates that cells genetically marked by *LysM^{Cre}* do not differentiate into LECs during normal murine development and is in agreement with another report using the *LysM^{Cre}* line [9]. *LysM^{Cre}* mice were then crossed with *Vegfr2^{flox}* mice to determine whether deleting *Vegfr2* in myeloid cells affects the development of the lymphatic vasculature. Whole-mount immunofluorescence staining of ear skin for Lyve-1 revealed that the density of lymphatic vessels was not significantly different between *Vegfr2^{flox/flox}* (8.550 ± 0.278 , $n = 5$ mice) and *LysM^{wt/Cre};Vegfr2^{flox/flox}* (9.150 ± 0.5895 , $n = 5$ mice) littermates (Figure 9A-D). Furthermore, the diameter of lymphatic vessels was not significantly different between *Vegfr2^{flox/flox}* ($52.98 \mu\text{m} \pm 1.328$, $n = 5$ mice) and *LysM^{wt/Cre};Vegfr2^{flox/flox}* ($50.05 \mu\text{m} \pm 2.031$, $n = 4$ mice) littermates (Figure 9A-D). EBD was also effectively transported from injected hind paws to popliteal and iliac lymph nodes in all *Vegfr2^{flox/flox}* and *LysM^{wt/Cre};Vegfr2^{flox/flox}* mice (data not shown). Together, these data reveal that *Vegfr2* is not required in the myeloid lineage for the proper development of the lymphatic system. This demonstrates that the lymphatic phenotype of *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* mice is due to the ablation of *Vegfr2* in LECs, not macrophages.

KEY RESEARCH ACCOMPLISHMENTS:

- Demonstrated that the *Lyve-1^{Cre}* mouse can be used to delete floxed sequences in initial and collecting lymphatic vessels.
- Showed for the first time that *Vegfr2* expression by lymphatic endothelium is required for the proper development of the lymphatic vasculature.

- Specifically, I have demonstrated that Vegfr2 is required for the expansion of the developing lymphatic network, not the enlargement of lymphatic vessels. These findings go against the current dogma regarding Vegfr2's function in lymphangiogenesis.

REPORTABLE OUTCOMES:

Accepted Manuscripts

- Witte MH, **Dellinger MT**, Papendieck CM, Boccardo F. 2012. Overlapping biomarkers, pathways, processes and syndromes in lymphatic development, growth and neoplasia. *Clinical and Experimental Metastasis*. (In Press).

Manuscript In Preparation

- Dellinger MT**, Hirashima M, Brekken RA. VEGFR2 directly regulates the development of the lymphatic vasculature. (*Manuscript in preparation*).

Poster Presentations

- Dellinger MT** and Brekken RA. Phosphorylation of Akt and ERK1/2 is required for VEGF-A/VEGFR2-induced proliferation and migration of lymphatic endothelium. *Gordon Research Conference: Molecular Mechanisms in Lymphatic Function & Disease* (March 4-9, 2012; Ventura, CA).
- Dellinger MT***, Hirashima M, Brekken RA. VEGFR2 directly regulates the development of the lymphatic vasculature. *NAVBO Developmental Vascular Biology Workshop V* (October 14-18, 2012; Pacific Grove, CA).

*This presentation won an award.

CONCLUSIONS:

VEGFR2 is widely recognized as an essential gene driving developmental and tumor angiogenesis. The present study demonstrates for the first time that VEGFR2 also directly promotes the development of the lymphatic vasculature. We show that the density, but not diameter, of lymphatic vessels is dramatically reduced in *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* mice. Additionally, we demonstrate that lymphatic vessels in *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* mice properly mature into collecting vessels. These findings indicate that VEGFR2 is required for the expansion of the lymphatic vessel network but not the maturation of the lymphatic system. This newly identified function of VEGFR2 further defines the molecular pathways controlling the development of the lymphatic vasculature and sheds light on how therapeutic agents targeting VEGFR2 can inhibit tumor lymphangiogenesis.

REFERENCES:

1. Pham, T.H., et al., *Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning*. J Exp Med, 2010. **207**(1): p. 17-27.
2. Muzumdar, M.D., et al., *A global double-fluorescent Cre reporter mouse*. Genesis, 2007. **45**(9): p. 593-605.
3. Petrova, T.V., et al., *Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis*. Nat Med, 2004. **10**(9): p. 974-81.
4. Makinen, T., et al., *PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature*. Genes Dev, 2005. **19**(3): p. 397-410.
5. Dellinger, M., et al., *Defective remodeling and maturation of the lymphatic vasculature in Angiopoietin-2 deficient mice*. Dev Biol, 2008. **319**(2): p. 309-20.
6. Wigle, J.T. and G. Oliver, *Prox1 function is required for the development of the murine lymphatic system*. Cell, 1999. **98**(6): p. 769-78.
7. Karkkainen, M.J., et al., *Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins*. Nat Immunol, 2004. **5**(1): p. 74-80.
8. Gordon, E.J., N.W. Gale, and N.L. Harvey, *Expression of the hyaluronan receptor LYVE-1 is not restricted to the lymphatic vasculature; LYVE-1 is also expressed on embryonic blood vessels*. Dev Dyn, 2008. **237**(7): p. 1901-9.
9. Gordon, E.J., et al., *Macrophages define dermal lymphatic vessel calibre during development by regulating lymphatic endothelial cell proliferation*. Development, 2010. **137**(22): p. 3899-910.

APPENDICES:




Figure 1. Cre recombinase-mediated deletion of *floxed* sequences in dermal lymphatic vessels. (A,B) Whole-mount preparations of ear skin from *mT/mG* and *Lyve-1^{wt/Cre};mT/mG* mice. GFP is not expressed in the skin of *mT/mG* mice (A) but is expressed by lymphatic vessels and macrophages in the skin of *Lyve-1^{wt/Cre};mT/mG* mice (B). (C-H) Representative images of transverse sections of ear skin from adult *Vegfr2^{flox/flox}* mice and *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* mice stained with antibodies against Vegfr2 and Lyve-1. Vegfr2 (C) is expressed by Lyve-1 positive (D) lymphatic vessels in *Vegfr2^{flox/flox}* mice (E, arrow). In contrast, Vegfr2 (F) expression is lost by Lyve-1 positive (G) lymphatic vessels in *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* mice (H, arrow).




Figure 2. *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* mice exhibit a deficiency of dermal lymphatic vessels. (A,B) Whole-mount immunofluorescence staining of ear skin from *Vegfr2^{flox/flox}* and *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* mice for Lyve-1. (C) Quantitative analysis showing that there are significantly fewer lymphatic branch points in the ear skin of *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* mice (6.042 ± 0.198 , $n = 6$) than *Vegfr2^{flox/flox}* mice (11.29 ± 0.940 , $n = 6$). (D) Lymphatic vessel diameter is not significantly different between *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* ($52.65 \mu\text{m} \pm 1.303$, $n = 6$) and *Vegfr2^{flox/flox}* mice ($49.05 \mu\text{m} \pm 1.675$, $n = 6$). *** indicates $P < 0.001$.




Figure 3. Lymphatic maturation and blood vessel patterning are normal in *Lyve-1^{wt/Cre}; Vegfr2^{flox/flox}* mice. Whole-mount immunofluorescence staining of ear skin from adult *Vegfr2^{flox/flox}* and *Lyve-1^{wt/Cre}; Vegfr2^{flox/flox}* mice for Lyve-1 (A,B), smooth muscle actin (A,B), and CD31 (C-F). (A,B) Lyve-1 positive lymphatic vessels are not covered by SMA positive cells in *Vegfr2^{flox/flox}* or *Lyve-1^{wt/Cre}; Vegfr2^{flox/flox}* mice. (C,D) CD31 expressing lymphatic valves are present in the collecting vessels of *Vegfr2^{flox/flox}* and *Lyve-1^{wt/Cre}; Vegfr2^{flox/flox}* mice. (E,F) The patterning of CD31 labeled blood vessels is similar for *Vegfr2^{flox/flox}* and *Lyve-1^{wt/Cre}; Vegfr2^{flox/flox}* mice.




Figure 4. Lymphatic drainage is normal in *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* mice. (A,B)
Intradermally administered EBD is transported from the hind paws to the iliac lymph nodes in all *Vegfr2^{flox/flox}* (n = 6) and *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* mice (n = 6).




Figure 5. *Lyve1^{wt/Cre};Vegfr2^{flox/flox}* embryos do not exhibit lymphatic defects. (A) Graph showing the percentage of viable *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* mice at different developmental stages. (B,C) Immunofluorescence staining for Lyve-1 showing jugular lymph sacs in E14.5 *Vegfr2^{flox/flox}* and *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* embryos. (D) The density of dermal lymphatic vessels is not significantly different between E16.5 *Vegfr2^{flox/flox}* and *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* embryos. (E,F) Representative images showing podoplanin positive dermal lymphatic vessels (arrows) in E16.5 *Vegfr2^{flox/flox}* and *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* embryos. (G-J) Images of non-edematous E14.5 (G,H), E16.5 (I) and E18.5 (J) *Vegfr2^{flox/flox}* embryos and *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* embryos.




Figure 6. *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* embryos display reduced blood vessel density in the yolk sac and liver. (A,B) Whole-mount immunofluorescence staining of yolk sacs from E12.5 *Vegfr2^{flox/flox}* and *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* embryos for CD31. (C) There are significantly fewer blood vessel branch points in yolk sacs from *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* embryos (41.06 ± 3.662 , $n = 4$ embryos) than *Vegfr2^{flox/flox}* embryos (106.3 ± 3.157 , $n = 3$ embryos). (D-F) Immunohistochemical staining of E14.5 livers for endomucin showing significantly fewer blood vessels in *Lyve-1^{wt/Cre};Vegfr2^{flox/flox}* embryos (27.00 ± 4.263 , $n = 4$ embryos) than in *Vegfr2^{flox/flox}* embryos (45.88 ± 2.850 , $n = 4$ embryos). ** indicates $P < 0.01$; *** indicates $P < 0.001$.




Figure 7. Macrophages do not express Vegfr2. (A-C) Whole-mount immunofluorescence staining showing a GFP (Vegfr2)-negative-Lyve-1-positive macrophage in the ear skin of a *Vegfr2*^{wt/GFP} mouse.




Figure 8. *LysM^{Cre}* is not expressed by lymphatic endothelial cells. (A,B) GFP is not expressed in ear skin from *mT/mG* mice. (C) GFP expression by macrophages is shown in a whole-mount preparation of ear skin from an adult *LysM^{wt/Cre};mT/mG* mouse. (D) GFP (green) does not co-localize with VEGFR3 (red) in the ear skin of a *LysM^{wt/Cre};mT/mG* mouse.




Figure 9. Deleting *Vegfr2* in the myeloid lineage does not affect the development of the lymphatic system. (A,B) Whole-mount immunofluorescence staining of ear skin from *Vegfr2^{flox/flox}* and *LysM^{wt/Cre};Vegfr2^{flox/flox}* mice for Lyve-1. (C) Quantitative analysis showing that the number of lymphatic branch points in the ear skin of *Vegfr2^{flox/flox}* (8.550 ± 0.278 , n = 5 mice) and *LysM^{wt/Cre};Vegfr2^{flox/flox}* mice (9.150 ± 0.5895 , n = 5 mice) are not significantly different from one another. (D) Furthermore, lymphatic vessel diameter is not significantly different between *Vegfr2^{flox/flox}* ($52.98 \mu\text{m} \pm 1.328$, n = 5 mice) and *LysM^{wt/Cre};Vegfr2^{flox/flox}* mice ($50.05 \mu\text{m} \pm 2.031$, n = 4 mice).